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Abstract
Introduction: New signaling pathways of the interleukin (IL) family, interferons (IFN) and interferon regulatory
factors (IRF) have recently been found within tumor microenvironments and in metastatic sites. Some of these
cytokines stimulate while others inhibit breast cancer proliferation and/or invasion. IRFs, a family of nine
mammalian transcription factors, have multiple biologic functions that when dysregulated may contribute to
tumorigenesis; most well-known are their roles in regulating/initiating host immunity. Some IRF family members
have been implicated in tumorigenesis yet little is still known of their expression in primary human tumors or their
role(s) in disease development/progression. IRF5 is one of the newer family members to be studied and has been
shown to be a critical mediator of host immunity and the cellular response to DNA damage. Here, we examined
the expression of IRF5 in primary breast tissue and determined how loss of expression may contribute to breast
cancer development and/or progression.
Methods: Formalin-fixed paraffin-embedded archival breast tissue specimens from patients with atypical ductal
hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) were examined for their
expression of IRF1 and IRF5. Knockdown or overexpression of IRF5 in MCF-10A, MCF-7 and MDA-MB-231 mammary
epithelial cell lines was used to examine the role of IRF5 in growth inhibition, invasion and tumorigenesis.
Results: Analysis of IRF expression in human breast tissues revealed the unique down-regulation of IRF5 in patients
with different grades of DCIS and IDC as compared to IRF1; loss of IRF5 preceded that of IRF1 and correlated with
increased invasiveness. Overexpression of IRF5 in breast cancer cells inhibited in vitro and in vivo cell growth and
sensitized them to DNA damage. Complementary experiments with IRF5 siRNAs made normal mammary epithelial
cells resistant to DNA damage. By 3-D culture, IRF5 overexpression reverted MDA-MB-231 to normal acini-like
structures; cells overexpressing IRF5 had decreased CXCR4 expression and were insensitive to SDF-1/CXCL12-
induced migration. These findings were confirmed by CXCR4 promoter reporter assays.
Conclusions: IRF5 is an important tumor suppressor that regulates multiple cellular processes involved in the
conversion of normal mammary epithelial cells to tumor epithelial cells with metastatic potential.
Introduction
Breast cancer is a heterogenous disease whose progres-
sion from atypical ductal hyperplasia (ADH) to ductal
carcinoma in situ (DCIS) and invasive ductal carcinoma
(IDC) is regulated by the aberrant expression of multiple
mediators produced by the mammary tumor itself and
the adjacent reactive stroma [1]. These signals promote
tumor cell proliferation, survival, establishment of tumor
vasculature, invasion and ultimately metastasis to sec-
ondary organs. The ability of the tumor to create a state
of local immune suppression allows tumor cells to evade
clearance by the immune system [2]. Signaling pathways
that regulate cytokine/chemokine expression (ILs, IFNs
and interferon regulatory factors (IRFs)) have recently
been found within tumor microenvironments and in
metastatic sites; some of these cytokines stimulate while
others inhibit breast cancer proliferation and/or invasion
[2]. The role of these cytokines in disease progression,
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tegies requires further attention.
IRF5 is a transcription factor that regulates type I IFN
signaling [3] and cytokines/chemokines with lympho-
cyte-chemotactic activities, that is, RANTES, MIP1a/b,
MCP1, I309, IL8 and IP10 [4]. Subsequent studies
demonstrated its critical role(s) in the cellular response
to extracellular stressors including virus, DNA damage,
Toll-like receptor (TLR) and death receptor signaling
[3-11]. Depending on the cell type, loss of IRF5 yields
cells incapable of a sufficient immune response to
pathogens and/or undergoing apoptosis [6,8-11]. North-
ern blot analysis of IRF5 tissue-specific expression
revealed that it is primarily expressed in lymphoid tis-
sues but can be induced in multiple cell types [3,12,13].
IRF5 has been associated with the regulation of impor-
tant cellular processes, such as cell growth, apoptosis,
cell cycle arrest, and cytokine production [6-9,14].
Little is known of IRF5 tumor suppressor function.
IRF5 was mapped to chromosome 7q32 [3] that con-
tains a cluster of imprinted genes and/or known chro-
mosomal aberrations and deletions in lymphoid,
prostate, and breast cancer [15-22]. IRF5 expression is
absent or significantly decreased in immortalized tumor
cell lines and primary samples from patients with hema-
tological malignancies, suggesting for the first time its
role as a tumor suppressor gene [3,7]. Recent data from
irf5
-/- mice support its candidacy as a tumor suppressor
gene [9]. Mouse embryonic fibroblasts (MEFs) from
irf5
-/- mice are resistant to DNA damage-induced apop-
tosis and can be transformed by c-Ha-ras [9]. Conver-
sely, ectopic expression suppresses malignancy of cancer
cell lines in vitro and in vivo [7,23]. While IRF5 has
been shown to be a direct target of p53 [23], data from
our lab and others indicate that IRF5 acts on an apopto-
tic signaling pathway that is distinct from p53 [7-9].
Loss of tumor suppressor genes represents a critical
event in the development and progression of breast can-
cer. However, while an increasing number of oncogenes
have been identified in breast cancer, few tumor sup-
pressor genes have been directly implicated in the devel-
opment/progression of this disease. Altered expression
or function of tumor suppressor genes BRCA1, BRCA2
and p53 do not fully account for the high prevalence of
spontaneous breast cancers. Loss or mutation of BRCA1
occurs in < 10% of all breast cancers, while p53 is
mutated in up to 30% of breast cancers [24]. There are
likely other tumor suppressor genes and oncogenes con-
tributing to breast tumorigenesis. IRF1 was recently
shown to have tumor suppressor function in breast can-
cer, while increased expression of IRF2 was associated
with oncogenic activation [25]. Overexpression of IRF1
induced apoptosis and inhibited tumor growth in mouse
and human mammary cancer cells [26-28]. The focus of
t h ep r e s e n ts t u d yw a st oe x a m i n ea n dc o m p a r eI R F 1
and IRF5 expression in human breast tissue and to
determine whether IRF5 acts as a tumor suppressor.
Data presented here support a unique role for IRF5 in
regulating mammary epithelial cell growth and provide
the first direct evidence that loss of IRF5 tumor sup-
pressor function contributes to breast tumorigenesis.
Materials and methods
Cell lines and culture
Human immortalized breast cells MCF-12A, MCF-7,
MDA-MB-231, -436, -468, and T47D were purchased
from American Type Culture Collection (Manassas, VA,
USA) in spring 2009, and aliquots were frozen in liquid
nitrogen until time of use. Cells were cytogenetically
tested and authenticated (by STR profiling from ATCC)
before freezing. The amphotrophic helper-free Phoenix
cells were provided by G. Nolan (Stanford, CA, USA).
All breast cancer cells lines and 293T-derived Phoenix
cells were propagated in Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich, St. Louis, MO, USA) contain-
ing 10% fetal bovine serum (Sigma) and 1 IU penicillin/
1 μl/ml streptomycin (Mediatech, Hemdon, VA, USA)
at 37°C in a humidified incubator with 5% CO2/95% air.
MCF-12A were grown in DMEM F-12 supplemented
with 5% horse serum (Sigma), 100 ng/ml cholera toxin
(Sigma), 20 ng/ml EGF (Invitrogen, Carlsbad, CA, USA),
10 μg/ml insulin (Sigma), and 500 mg/ml hydrocorti-
sone (Sigma). Each vial of frozen ATCC authenticated
cells was thawed and maintained in culture for a maxi-
mum of six weeks. There were enough frozen vials for
each cell line to ensure that all experiments were per-
formed on cells that had been tested and in culture for
six or more weeks.
Chemicals and treatments
Doxorubicin was from Sigma; Interferon (IFN)-g from
PBL InterferonSource (Piscataway, NJ, USA). Cells were
treated with 0.1 or 1 μM Doxorubicin or 1,000 U/ml
IFN-g for the indicated time periods. Cells were exposed
to 2, 5 or 10 Gray (Gy) of ionizing radiation (IR) using a
self-shielded Cs-137 irradiator.
Retroviral construction and transduction
IRF5 was cloned into the pBabe-puromycin vector at
BamHI/SalI sites transfected to Phoenix cells as
described [29]. Viral supernatants were collected 48 h
post-transfection and used to infect MCF-7, MDA-MB-
231 and -468 cells. After two days, media was
exchanged for puromycin selection to obtain stable
transfectants. Cultures were pooled from each cell line
and positive infection determined by Western blot with
mouse anti-IRF5 antibodies (M01, Novus Biologicals,
Littleton, CO, USA).
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and semi-quantitative evaluation
H&E sections of formalin-fixed paraffin-embedded (FFPE)
archival tissue specimens were reviewed by two patholo-
gists (MH and NM) for histological evaluation of disease
and grade. Slides from 19 patients with ADH, 24 with
DCIS, 29 with IDC, and 11 with lymph node metastases
were evaluated for IRF expression. Normal breast tissue
from the same donors or adjacent to tumors were charac-
terized in 51 patients. Sections were obtained from the
Pathology Department at UMDNJ New Jersey Medical
School (NJMS). The study was approved by the NJMS
Institutional Review Board (IRB) and all participants pro-
vided written informed consent. Antigen retrieval was per-
formed by heating slides at 95°C in citrate buffer (pH 6.0)
for one hour before staining with mouse anti-IRF5 or rab-
bit anti-IRF1 (C-20, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) antibodies at 1:100 dilution in 4% BSA
overnight. For IF, slides were incubated with anti-rabbit
Cy3 and anti-mouse FITC (Molecular Probe, Eugene, OR,
USA) antibodies at 1:1,000 in 4% BSA/PBST. Slides were
mounted with DAPI mounting buffer (Vector Labora-
tories, Burlingame, CA, USA) and images captured on a
Zeiss Axiovert 200 fluorescent microscope; quantification
was performed using Axiovision software (Carl Zeiss
Microimaging, Oberkochen, Germany). For IHC, slides
were incubated with 1:200 diluted anti-IRF5 for two hours
then 1:1,000 diluted Alkaline Phosphatase anti-mouse IgG
(Vector Laboratories, AP-2000) and developed with the
Vector
® Blue Alkaline Phosphatase (BAP) Substrate Kit III
(Cat. No. SK-5300). The second staining was with 1:200
diluted anti-IRF1, Peroxidase anti-Rabbit IgG (Vector
Laboratories, PI-1000) and developed with DAB Substrate
Kit (Vector Laboratories, SK-4100). The nucleus was
stained with Nuclear Fast Red mounting buffer.
Evaluation of stained slides was assessed by one
pathologist (MH) and two independent reviewers (XB
and BJB or JA), who were unaware of the patient’s char-
acteristics. Two slides from different areas of the same
tumor were examined and scored independently by each
reviewer with a consensus being reached in difficult
cases (< 5% for each antibody). Following initial review,
an arbitrary grading system was defined for each anti-
body in which the density of positive cells within normal
ducts and lobules or ADH, DCIS and IDC as defined by
the tumor (and not the stroma) was assessed semi-quan-
titatively on the whole tissue section. This classification
allowed the stratification of the tumors as positive or
negative for IRF1 and IRF5.
Western blotting
Preparation of cellular lysates and immunoblotting were
performed as described [30,31]. Proteins were trans-
ferred to nitrocellulose membrane and detected with
horseradish peroxidase (HRP)-conjugated secondary
antibody (1:2,000) followed by enhanced chemilumines-
cence (Amersham Biosciences, Piscataway, NJ, USA).
Equal loading was confirmed with b-actin antibodies
(Cell Signaling, Danvers, MA, USA) after stripping with
Restore™ Western blot stripping buffer (Pierce, Rock-
ford, IL, USA).
Colony survival assay
Colony survival was performed as described [31]. Cells
were plated and exposed to different sources of DNA
damage. One hour post-treatment, cells were split into
2,000 cells per 10 cm plate and cell growth assessed
after 14 days by staining with 0.5% crystal violet and
25% methanol. The colony number was calculated and
plotted as the mean for triplicate samples and presented
as percentages relative to the control.
Apoptosis assay
Apoptosis was assessed by flow cytometric analysis of
cells stained with Annexin V-FITC and PI using a Bec-
ton Dickinson FACScan (St. Louis, MO, USA) [8,10].
Data analysis using CELLQuest™ software (Becton
Dickinson) was performed; numbers of cells positive for
Annexin V-FITC, PI, or combinations thereof, were
calculated.
Suppression of IRF5 with siRNA
A modified protocol from Hu et al. [10] was used to
transfect siRNAs into immortalized non-oncogenic
mammary epithelial cells. MCF-12A cells were trans-
fected using Qiagen (Valencia, CA, USA) RNAifect
Transfection Reagent once with 5 nM of IRF5 pooled
siRNAs (Catolog #16708; Ambion, Austin, TX, USA)
and harvested 24 h later, or twice (transfected a second
time at the 24 h timepoint) and harvested an additional
24 h later. siGenome Lamin A/C Control siRNA (Cata-
log #D-001050-01-05; Dharmacon, Lafayette, CO, USA)
was transfected in a similar manner. Knockdown of
IRF5 was determined from Western blots by densitome-
try analysis of the mean pixel intensity of IRF5 normal-
ized to b-actin.
3-Dimensional (3-D) culture in Matrigel and PCR array
3-D culture was performed as described [32]. Cells were
spread between two layers of Matrigel (Becton Dickin-
son) in eight-well chamber slides. Slides were incubated
at 37°C in 5% CO2/95% air for 10 days. Acini formation
was visualized on a Zeiss microscope at 10 × magnifica-
tion. 3-D colonies were harvested with Cultrex 3D cul-
ture Matrix™Cell Harvesting Kit (3448-020-K, Trevigen,
Gaithersburg, MD, USA) following the manufacturer’s
instruction and total RNA isolated with Qiagen RNeasy
Plus Mini kit (#74134). Total RNA was converted to
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ciences #84034; Gaithersburg, MD, USA) for PCR array
and qPCR analysis. The effect of IRF5 overexpression on
84 known tumor metastases genes was analyzed using
the Human Tumor Metastasis RT
2 Profiler™ PCR
Array (SABiosciences PAHS-028A-2; Frederick, MD,
USA) using RT
2 SYBR
® Green qPCR Master Mixes
(SABiosciences, PA-012); qPCR was performed on the
ABI 7300 instrument. Raw data were analyzed with
SABiosciences online data analysis software. For stan-
dard q2PCR, iTaq™SYBR Green Supermix with Rox
(Bio-Rad 172-5850; Hercules, CA, USA) was used. Pri-
mer sequences for standard qPCR are shown in Addi-
tional file 1, Table S1 obtained from the Quantitative
PCR Primer Database [33].
Chemotaxis assay
Chemotaxis assays were performed using 24-well trans-
well permeable supports (Corning Life Sciences, Lowell,
MA, USA) in accordance with the manufacturer’s
instructions. Briefly, 100 ng/ml human recombinant
CXCL12/SDF-1 (R&D Systems, Minneapolis, MN, USA)
was added to 600 μl of phenol red-free DMEM medium
supplemented with 10% FBS in the lower chamber. A
total of 1 × 10
5 MDA-MB-231 cells in 100 μlo fm e d -
ium were added to the upper chamber, separated from
the lower chamber by a membrane (6.5 mm diameter, 8
μM pore size, polycarbonate membrane). Total cell
migration was obtained by calculating cell number in
the lower chamber after 6 hr of incubation at 37°C in
5% CO2. Three samples were analyzed separately in
duplicate, and the data were averaged for statistical
analysis.
Cell surface expression of CXCR4
Cell surface expression of CXCR4 was measured by flow
cytometry. MDA-MB-231 cells cultured with and with-
out 100 ng/ml CXCL12 for six hours were stained with
PE-conjugated anti-human CXCR4 antibodies or isotype
control antibodies (BioLegend, San Diego, CA, USA) in
accordance with the manufacturer’s specifications. In
brief, cells were harvested, washed in PBS, mixed with
the appropriate antibody and incubated in the dark for
15 minutes before analysis by flow cytometry. A total of
10,000 events were accumulated for each analysis; sam-
ples were analyzed in triplicate.
CXCR4 promoter reporter assay
A total of 1 × 10
6 MDA-MB-231/pBabe or MDA-MB-
231/pBIRF5 cells were plated in 96-well format in tripli-
cate four hours before transfection (SuperFect Transfec-
tion Reagent, Qiagen) with pGL3 empty vector control
plasmid or the CXCR4 luciferase promoter reporter
pGL3-CXCR4/3B/4-1(5’Δ3) (-191 to +88) [34] from Dr.
Nelson L. Michael (Walter Reed Army Institute of
Research). In all wells, 40 ng of thymidine kinase driven
Renilla luciferase reporter gene (Promega, Madison, WI,
USA) was co-transfected to normalize for transfection
efficiency. After 24 h of transfection, fresh media was
added to cells with or without 100 ng/ml CXCL12 for 4
h. Post-stimulation, cell lysates were prepared, and
reporter gene activity was measured using the Dual luci-
ferase assay system (Promega) [5]. Data are expressed as
the mean relative stimulation ± S.D.
In vivo tumorigenicity assay
Four- to six-week ovariectomized, Ncr nu/nu mice (n =
18 per group (Charles Rivers Laboratory, Wilmington,
MA, USA) were supplemented with 17 b-estradiol pel-
lets (0.72 mg/pellet; Innovative Research of America,
Sarasota, FL, USA) and used to determine the tumori-
genicity of MCF-7 pooled stable transfectants [26]. A
total of 1 × 10
6 control (MCF-7/pBabe) or MCF-7/
pBIRF5 cells were inoculated into opposite thoracic
mammary fat pads. Ncr nu/nu mice (n =1 5p e rg r o u p )
were also used for MDA-MB-231 pooled stable transfec-
tants. A total of 2 × 10
6 control (MDA-MB-231/pBabe)
or MDA-MB-231/pBIRF5 cells were inoculated into
upright mammary fat pads. The primary endpoint was
the incidence of proliferating tumors; secondary was
tumor size. Tumor areas were estimated from the pro-
duct of the two longest perpendicular measurements
with a caliper. All in vivo studies were conducted in
accordance with UMDNJ New Jersey Medical School
Animal Care and Use Committee approved protocols.
Statistical analyses
Data are presented as mean ± SD of data obtained from
three or four independent experiments performed in
duplicate. Representative experiments of multiple
experiments are depicted in some figures. Comparisons
between values were analyzed by the Student’s t-test.
Differences were considered significant at P-values ≤
0.05. Statistical analyses were performed using Prism 4.0
(GraphPad Software, San Diego, CA, USA). Cumulative
incidences of proliferating tumors in each experimental
group were visualized by the Kaplan-Meier method and
compared by the log rank test.
Results
Loss of IRF expression in human breast tumor tissues
IRF1 and IRF5 expression were examined in FFPE speci-
mens from patients with different stages of breast cancer
by IF and IHC. Normal ducts gave diffuse cytoplasmic
and nuclear staining for IRF1, as shown by the purple
color in the merged IF panel, as well as IHC, that was
consistent with previous findings [25]. In contrast, IRF5
staining appeared primarily diffuse cytoplasmic. Staining
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was highly expressed in luminal epithelial cells lining
the duct and IRF5, while also detected at low levels in
these cells, was more focused and pronounced in ductal
myoepithelial cells (MECs); results from IF of normal
ducts and ADH support the differential cellular expres-
sion of IRF1 and IRF5 (Figure 1A). Co-staining with
cytokeratin 14 (CK14) confirmed expression of IRF5 in
MECs (Figure 1B).
Of the 19 patients with ADH, 100% showed positive
staining for IRF1 and IRF5 (Figures 1A and 2A). Most
DCIS breast cancers retained expression of IRF1 in
tumor tissue with 23 out of 24 staining positive, whereas
IRF5 expression was significantly reduced with only 9
out of 24 staining positive (Figures 1C and 2A). A dis-
tinct trend was observed when examining IRF5 expres-
sion in low and high grades of DCIS marking a grade-
dependent decrease in expression (Figure 2B). Of the 29
patients with IDC, only 7 retained IRF1 expression and
3 had IRF5 (Figure 1C, 2A). Throughout our analysis of
stained slides, reviewers noted that IRF5 and not IRF1
expression was often detected in the surrounding stroma
of DCIS and IDC patients (Figure 1).
Review of pathology data, including grade as scored by
the original clinical pathologist, estrogen (ER), proges-
terone (PR), and Her2 receptor status, was performed by
Dr. Hameed, a licensed pathologist, under an approved
NJMS IRB. Given the small sample size, it was difficult
to make statistical correlations between receptor and
IRF expression; however, data at present suggest that
loss of IRF5 expression correlates with ER/PR(-) breast
cancers in 82 to 90% of samples. Loss of Her2/neu
expression did not correlate with IRF5 expression. Eva-
luation of IRF1 expression in relation to tumor charac-
teristics gave no correlations [25].
IRF5 modulates cell growth and response to DNA damage
We next examined IRF1 and IRF5 protein expression in
immortalized tumorigenic mammary epithelial cells and
non-oncogenic mammary epithelial cell lines to confirm
findings in primary tissues. IRF1 and IRF5 levels were
consistently reduced in breast cancer cell lines com-
pared to non-oncogenic mammary epithelial MCF-12A
cells (Figure 3A); similar findings were made at the tran-
script level by Q-PCR (data not shown or Additional file
2). To address the functional consequence of this loss,
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Figure 1 Dysregulated IRF expression in patients with ductal carcinoma. A. Normal and ADH breast tissue specimens were stained by IF or
IHC. Antibodies recognizing IRF5 (FITC), IRF1 (Cy3) and DAPI for the nucleus were used for IF. For IHC, tissues were stained for IRF1 with DAB
(brownish-red), IRF5 with BAP (blue), and nucleus with Fast Red mounting buffer. B. Same as in (A), except tissue samples from patients with
ADH were stained by IF with IRF5 (FITC) and CK14 (Cy3) in order to confirm expression of IRF5 in myoepithelial cells. C. Same as in (A), except
tissues from patients with DCIS and IDC were examined. Representative pictures of low grade and high grade DCIS are shown illustrating
distinct differences between IRF1 and IRF5 expression. Images were taken on a Zeiss Axiovert Apotome microscope at 20 × or 40 ×
magnification. Scale bars are 50 μm.
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cell lines that had little or no endogenous expression.
MCF-7 (ER(+), low invasive) and MDA-MB-231 (ER(-),
highly invasive and tumorigenic) cells were generated to
stably overexpress IRF5 by retroviral infection (Figure
3B). Control lines expressing empty vector pBabe were
g e n e r a t e da tt h es a m et i m ea n dc o n f i r m e dt og r o wa n d
respond identical to parental cells (data not shown). The
colony formation assay was used to determine the effect
of IRF5 on cell growth. IRF5 reduced colony formation
by approximately 20% as compared to unstimulated
empty vector controls (Figure 3C). These data are con-
sistent with earlier findings of IRF5 function in lym-
phoma, lung and colon cancer cells [7,8,23]. Depending
on cell type, IRF5 can have little effect on growth or
apoptosis in unstimulated cells [7,8]. IRF5 generally
requires activation and nuclear localization for its biolo-
gical function [7,8]; however, transient or stable overex-
pression has been demonstrated to push IRF5 into the
nucleus resulting in low but significant growth
inhibition [3,4,7,8,23]. To determine whether IRF5 func-
tion in breast cancer was dependent on DNA damage,
cells were treated with Doxorubicin (Dox) or exposed to
g-irradiation (IR). IRF5 sensitized cells to DNA damage-
induced growth inhibition in a similar dose-dependent
manner independent of the source of damage both in
2D culture (data not shown) and in colony formation
assay (Figure 3C). These data support that IRF5
enhances DNA damage-induced growth inhibition.
To determine whether the observed growth inhibition
was due to IRF5-mediated apoptosis or necrosis, we
measured AnnV-FITC and PI-double staining by flow
cytometry. Overexpression in untreated MDA-MB-231
cells (MDA-MB-231/pBIRF5) induced apoptosis
approximately 2.5-fold over empty vector control cells
(Figure 4A). No significant difference in total AnnV-
FITC positive-stained cells was observed between
untreated and IR-treated cells; yet, when compared to
IR-treated empty vector control cells, IRF5 provided an
approximately 40% increase in positive-stained cells.
Combinations of IR/IFN-g with IRF5 provided a syner-
gistic induction of apoptosis. Similarly, MDA-MB-231/
pBIRF5 cells were sensitized to Dox-induced apoptosis
while no synergistic or additive effects were observed
with IFN-g (Figure 4B). Overexpression of IRF5 in
MCF-7 cells (MCF-7/pBIRF5) had no significant effect
on IR- or Dox-induced apoptosis; cells were also resis-
tant to combinations with IFN-g (Figure 4C and data
not shown). Previous data from our lab showed a syner-
gistic effect of DNA damage and type I (a and b)o rI I
(g) IFNs [7,8]. IFN-g on its own has very little effect on
MCF-7 or MDA-MB-231 cells [35] (data not shown).
Whether the differential effects observed between these
two cell lines were due to ER status or other genetic/
biological differences is unclear at this time. Nonethe-
less, data in Figures 3 and 4 indicate that IRF5-mediated
growth inhibition is in part independent of its ability to
mediate apoptosis.
IRF5 knock-down in immortalized non-oncogenic
mammary epithelial cells confers protection from DNA
damage-induced growth inhibition and apoptosis
The fact that IRF5 is well expressed in immortalized
non-oncogenic mammary epithelial cells compared to
breast cancer cells and tumor tissues is consistent with
the concept that IRF5 is a tumor suppressor protein.
Overexpression studies confirm a role for IRF5 in cell
growth and response to DNA damage (Figures 3 and 4).
We next examined the direct consequences of loss of
IRF5 expression on the DNA damage response in
immortalized non-oncogenic mammary epithelial MCF-
12A cells. Western blot data in Figure 5A show > 70%
reduction of IRF5 proteins, as determined by densitome-
try analysis, after single (IRF5 siRNA1) or double (IRF5
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specimens. A. Percent of samples with positive staining is shown
on y-axis, tissue and disease type are shown on x-axis. Number of
samples positive for IRF1 or IRF5 is shown over total number of
patient samples examined in each group. Statistical significance was
determined by comparing the number of positive-stained samples
in each disease type to positive-stained samples in normal tissues; *
denotes P < 0.05, **P < 0.001. B. Same as in A, except expression in
different stages of DCIS is shown.
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duplexes (see Materials and methods). The double
transfection (IRF5 siRNA2) protocol, harvested at 48 h
post-transfection, was used in all further experiments
since it gave approximately 80% reduction. No differ-
ences in IRF5 expression or cellular growth were
observed in cells mock transfected or transfected with
control siRNAs (Figure 5A and data not shown). Knock-
down of IRF5 in MCF-12A cells resulted in significant
protection (> 50%) from normal or spontaneous apopto-
sis. Significant reductions in IR-induced apoptosis were
also observed, whereas little protection was offered in
response to Dox (Figure 5B, C). Significant protection
from Dox/IFN-g treatment was observed in cells trans-
fected with IRF5 siRNAs. Loss of IRF5 expression also
protected cells from DNA damage-induced growth inhi-
bition (Figure 5D). These data implicate IRF5 as a criti-
cal regulator of in vitro mammary epithelial cell growth
and response to DNA damage.
IRF5 modulates in vivo/in vitro tumor cell growth and
metastasis/invasion by regulating CXCR4 expression
To determine directly whether IRF5 could act as a
tumor suppressor in vivo, MCF-7/pBabe and MCF-7/
pBIRF5 cells were inoculated into NCr nu/nu mice. The
cumulative incidence of proliferating tumors was signifi-
cantly lower for MCF-7/pBIRF5 mice compared with
controls and the few tumors that formed (in 3 out of 18
mice) were significantly smaller than control (Figure 6A
and data not shown). Similar findings were made after
injection with MDA-MB-231/pBabe and MDA-MB-231/
pBIRF5 cells (Figure 6B).
Intracardiac or intravenous injection of MDA-MB-231
cells generates a rapid experimental model of tumor
metastasis. While injection of MDA-MB-231 cells into
mammary fat pads also models tumor metastasis, low
incidence of primary tumor formation (50% of mice)
and later metastases (approximately 20%) was observed.
Nonetheless, mice injected with MDA-MB-231/pBIRF5
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Figure 3 Overexpression of IRF5 in MCF-7 and MDA-MB-231 cells sensitizes them to DNA damage-induced growth inhibition. A.
Endogenous IRF expression was analyzed by Western blot in transformed mammary epithelial cell lines. Levels of b-actin are shown as loading
controls. B. Western blot analysis of stable cell lines generated to overexpress retroviral pBIRF5. C. Cell survival was measured in MCF-7 and MDA-
MB-231 pBabe cell lines by colony formation assay before and after treatment. Cells were treated with 0.1 or 1 μM Doxorubicin (Dox) or 2, 5 and
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0.001.
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Page 7 of 14cells that generated primary tumors showed no metas-
tases. This, combined with in vitro data suggesting other
mechanisms of IRF5-mediated growth inhibition, led us
to examine the effect of IRF5 on tumor cell metastasis/
invasion. By 3-D cell culture, IRF5 overexpression in
MDA-MB-231 but not MCF-7 cells inhibited acini out-
growth (Figure 6C). The lack of response in MCF-7
cells to IRF5 was expected given the low metastatic
potential of these cells. To determine how IRF5 inhib-
ited outgrowth, we examined expression of genes con-
tained in a pre-designed Human Tumor Metastasis PCR
array (see Materials and methods). Differences were
observed between pBabe and pBIRF5 cell lines; genes
showing differential regulation included CTSK, CXCR4,
HGF, ITGA7, MMP10,a n dRORB (Table 1).
Independent analysis of these genes confirmed a signifi-
cant down-regulation of CXCR4 by IRF5 (5- to -6-fold
decrease; P < 0.05) (Additional file 3).
To ensure that there is a correlation between CXCR4
mRNA and cell surface expression of the CXCR4 pro-
tein, we performed flow cytometric analysis. Cell surface
expression of CXCR4 in unstimulated MDA-MB-231
cells is very low and no significant difference was
observed in basal CXCR4 expression between MDA-
MB-231/pBabe (8.8%) and MDA-MB-231/pBIRF5 (6.4%)
cells (Figure 7A, shown by a grey line superimposed on
isotype control peak). Therefore, to ensure an accurate
measure of CXCR4 cell surface expression on MDA-
MB-231/pBabe and MDA-MB-231/pBIRF5 cells, cells
were incubated for six hours with the CXCR4 ligand
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Figure 4 Overexpression of IRF5 in MDA-MB-231 cells sensitizes them to IR-induced apoptosis. A. MDA-MB-231 cells were exposed to 5
Gy IR or the same dose plus IFN-g (IR/g) for 24 h. Percent of cells undergoing apoptosis was measured by FACS analysis of Annexin V-FITC (x-
axis) and PI (y-axis) double-staining. Percent of Annexin V-FITC stained positive cells is shown in the upper and lower right-hand quadrants.
Representative histogram plots from three independent experiments performed in duplicate are shown. B. Same as in (A), except cells were
treated with 1 μM Dox or the same dose plus IFN-g (Dox/g) for five hours. Percent of Annexin V-FITC-stained positive cells compared to control
is plotted on y-axis. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was
determined by comparing the difference between pBabe and pBIRF5 cells lines after each treatment; ** denotes P < 0.001. C. Same as in (B),
except MCF-7 cells were treated with Dox.
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Figure 5 Down-regulation of IRF5 protein expression by siRNAs alters sensitivity to DNA damage. A. MCF-12A cells were incubated with
transfection reagent alone (mock-transfected), control Lamin A/C siRNAs or 5 nM IRF5 siRNAs once (IRF5 siRNA1) or twice (IRF5 siRNA2), as
described in the Materials and methods. Western blot analysis shows > 70% reduction of endogenous IRF5 proteins after normalization to b-
actin levels. B. Cells were exposed to 5 Gy IR or the same dose plus IFN-g (IR/g) for 24 h. Percent of Annexin V-FITC stained positive cells is
shown in the upper and lower right-hand quadrants. Representative histogram plots from three independent experiments performed in
duplicate are shown. C. Same as in B, except cells were exposed to 1 μM Dox or Dox and IFN-g for five hours. Percent of Annexin V-FITC stained
positive cells compared to control is plotted on y-axis. Data are expressed as mean ± SD of three independent experiments performed in
duplicate. Statistical significance was determined by comparing the difference between cells transfected with Lamin A/C siRNAs (12Asicon) and
IRF5 siRNAs (12AsiIRF5) after each treatment; ** denotes P < 0.001. D. Cells were treated with the indicated doses of Dox or IR after siRNA
transfection. Number of colonies is plotted on y-axis as percent of control. A total of 100% represents the number of colonies in control
untreated 12Asicon cells. Data are expressed as mean ± SD of three independent experiments performed in duplicate. Statistical significance was
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Page 9 of 14SDF-1/CXCL12 to upregulate CXCR4 expression. Data
in Figure 7A clearly demonstrate the inability of MDA-
MB-231/pBIRF5 cells to express surface CXCR4 (shown
by black line). By chemotaxis assay, we show that MDA-
MB-231/pBIRF5 cells, as compared to MDA-MB-231/
pBabe cells, are incapable of migrating in response to
SDF-1 (Figure 7B). Furthermore, in the absence of SDF-
1/CXCL12, basal migration was significantly inhibited
supporting our findings in 3-D culture.
Since these data suggested that IRF5 may contribute
to the regulation of CXCR4 in breast cancer cells, we
performed a computer-based analysis of the human
CXCR4 gene promoter with MatInspector [36]; two IRF
binding elements (IRF-E) were identified. CXCR4 pro-
moter reporter assays were subsequently performed in
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Figure 6 IRF5 inhibits in vivo tumor formation and in vitro metastasis/invasion. A. MCF-7/pBIRF5 (MCF7-IRF5) and MCF-7/pBabe (MCF7-EV)
control cells were inoculated into NCr nu/nu mice. The number of mice with tumors over the total number of mice is shown. B. Same as in (A),
except 3 × 10
6 MDA-MB-231 control cells (231-EV) or MDA-MB-231 IRF5 overexpressing cells (231-IRF5) were inoculated into NCr nu/nu mice and
monitored over seven weeks. C. Growth of MCF-7 and MDA-MB-231 cells were examined by 3-D culture. An equal number of cells were plated
and pictures taken 10 days later at 10 × magnification.
Table 1 Genes differentially regulated by IRF5 in MDA-
MB-231 cells.
Gene Function Expression in pBIRF5 vs.
pBabe
CTSK
a Cathepsin K Decreased
CXCR4
b Receptor for CXCL12/SDF-1 Decreased
HGF
a Hepatocyte growth factor Decreased
ITGA7
b Integrina7 Decreased
MMP10
a Matrix metalloproteinase 10 Decreased
MMP3
b Matrix metalloproteinase 3 Increased
RORB
b Retinoid-related orphan
receptor b
Increased
adenotes genes with ≥ 2- to 3.99-fold change;
bgenes with ≥ 4- to 6.99-fold
change. Gene expression was compared between MDA-MB-231/pBabe and
MDA-MB-231/pBIRF5.
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Page 10 of 14MDA-MB-231/pBabe and MDA-MB-231/pBIRF5 cells.
Data in Figure 7C indicate basal transactivation of the
CXCR4 promoter that was significantly down-regulated
in cells expressing IRF5. Similar findings were made in
MCF-7 cells transfected with Flag-tagged IRF5 (data not
shown). Stimulation of MDA-MB-231/pBabe cells with
CXCL12/SDF-1 ligand greatly enhanced reporter
activity, while stable MDA-MB-231/pBIRF5 cells yielded
a significant decrease in ligand-induced transactivation.
These data confirm the negative regulation of CXCR4
expression by IRF5 in breast cancer cells.
Further support for IRF5 in regulating tumor metasta-
sis was obtained by examining IRF5 expression in clini-
cal metastatic lymph node tissues from IDC patients. As
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Figure 7 IRF5 reduces CXCR4 cell surface expression and SDF-1/CXCL12-dependent chemotaxis of MDA-MB-231 cells. A.C X C R 4
expression (grey line) in unstimulated cells, shown superimposed on the isotype control (grey shaded area), and CXCR4 expression (black line)
after stimulation, was measured by flow cytometry. MDA-MB-231 cells (pBabe and pBIRF5) were treated with the CXCR4 ligand SDF-1 for six
hours and CXCR4 expression measured. IRF5 expressing cells show no significant expression of CXCR4. M1, Marker 1. Representative histogram
plots from three independent experiments performed in duplicate are shown. B. Cells overexpressing IRF5 are incapable of SDF-1-induced
migration when compared to empty vector (EV pBabe) control cells. Data are expressed as mean ± SD of three independent experiments
performed in duplicate. Statistical significance was determined by comparing the difference in number of cells migrated between pBabe and
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expression, except one that showed very low levels
(Additional file 4), supporting a correlation between loss
of IRF5 expression and tumor metastases.
Discussion
Results presented here provide the first clear support of
IRF5 tumor suppressor function and identify a new role
for IRF5 in tumor cell invasion/metastasis. We demon-
s t r a t e dt h a tl o s so fI R F 5e x p ression correlated with
advanced stages of breast cancer and invasion/metasta-
sis. Loss of IRF5 preceded that of IRF1, but loss of IRF5
expression was not a prerequisite for IRF1 and IRF5
overexpression did not affect IRF1 levels (Figure 3A and
data not shown). IRF1 was used as a comparative con-
trol given its known expression and function in breast
cancer [25]. The differential reactivity of the IRF1 and
IRF5 antibodies by IF and IHC, as well as by Western
blot showing they bind to discrete molecular weight
bands (IRF1 approximately 48 kDa and IRF5 62 kDa),
support their specificity; in addition, the same IRF1 anti-
body used in the manuscript by Doherty et al. [25] to
examine IRF1 expression in FFPE samples was used in
this study. Two distinct IRF5 antibodies, one from
Novus Biologicals and the other from Cell Signaling,
were tested and gave identical results by IF, IHC and
Western blot analysis of IRF5 expression in immorta-
lized transformed and untransformed cell lines (data not
shown). Together, these data document both the specifi-
city and non-cross-reactivity of anti-IRF1 and anti-IRF5
antibodies.
Although we found that IRF1 and IRF5 were simi-
larly expressed in normal breast tissue and patients
with ADH or IDC, significant differences were
observed in DCIS suggesting the unique utilization of
these two biomarkers for diagnosis and prognosis.
Another important distinction between these two tran-
scription factors was in cellular expression; IRF5 was
predominantly expressed in MECs (Figure 1A, B). IRF5
w a sa l s od e t e c t e di nn o n - M E C sa n dt h es u r r o u n d i n g
stroma of early DCIS, late DCIS and IDC patients (Fig-
ure 1C). These data support distinct functions for IRF1
and IRF5 in breast tumorigenesis. MECs play a critical
role in mammary gland development and loss of myoe-
pithelial function is almost universally associated with
breast cancer [37]. MECs are localized between lumi-
nal epithelial cells and the stroma, which ideally posi-
tion them to communicate with both compartments.
They suppress tumor growth and invasion [38] and
degradation of the MEC layer and basement membrane
is an absolute prerequisite for breast cancer invasion
and metastasis [39]. Mounting evidence also demon-
strates the importance of surrounding stroma in tumor
promotion [40]. Recent data from Eguchi et al.s u p p o r t
a role for IRF5 in the fatty stroma [41]. Additional
experiments are necessary to determine the exact
expression and function of IRF5 in tumor versus non-
tumor MECs, stromal cells and non-MECs. Significant
differences in gene expression have been observed
between normal MECs and tumor MECs [42,43].
G i v e nt h ek n o w nf u n c t i o n ( s )o fI R F 5i nr e g u l a t i n g
proinflammatory cytokine/chemokine expression
[3,4,6], combined with its cellular expression in breast
tissue and high expression in infiltrating leukocytes in
the tumor stroma of IDC patients (Additional file 5),
suggest that IRF5 may play an important role in breast
cancer invasion. Indeed, the van’t Veer cohort placed
IRF5 in a dominant gene cluster associated with lym-
phocytic infiltration and progressive disease [44].
Furthermore, IRF5 is part of a 28-gene signature for
predicting breast cancer recurrent and metastatic
potential [45]. Based on data presented here, we pro-
pose a two-fold function for IRF5 that is cell type-spe-
cific and lends support to the ‘release’ model of breast
cancer invasion where phenotypic changes in MECs
(loss of IRF5 expression), in coordination with the
infiltration and influence of inflammatory cells (high
levels of IRF5 expression), lead to the breakdown of
ducts and release and invasion of tumor epithelial cells
[46].
Clinical data from tissue specimens combined with
expression analyses and 3-D cultures provide the first
clues that IRF5 may be involved in regulating tumor
metastases, where loss of IRF5 enhances metastatic
potential. A cursory review of the literature indicates
that this function is unique to IRF5 and not IRF1. The
molecular mechanism by which IRF5 inhibits invasion/
metastasis is not yet clear but likely involves the dysre-
gulation of genes, such as CXCR4. CXCR4,t h er e c e p t o r
for chemokine CXCL12/SDF-1, was significantly down-
regulated at both the transcript and protein level by
IRF5 overexpression, and IRF5 inhibited promoter
reporter activity (Figure 7A, C and Additional file 3).
CXCR4 is an important factor in the migration, inva-
siveness and proliferation of breast cancer cells and
silencing of CXCR4 blocks breast metastasis [47,48].
Increased expression of CXCR4 in primary breast
tumors has been associated with developing bone metas-
tases [49].
Further studies will be necessary to address the ques-
tion of how or why IRF5 expression is altered in differ-
ent stages of human breast cancer. Results from Q-PCR
analysis of IRF5 transcript expression (Additional file 2)
support the presence of IRF5 transcripts in cell lines
that lack detectable IRF5 proteins, that is, MDA-MB-
231 and T47D cells, yet the overall trend in IRF5 tran-
script and protein levels correlated. The IRF5 promoter
does contain a large CpG rich island [13] suggesting
Bi et al. Breast Cancer Research 2011, 13:R111
http://breast-cancer-research.com/content/13/6/R111
Page 12 of 14that it may be susceptible to silencing by hypermethyla-
tion; yet, when MDA-MB-231, MDA-MB-436 and T47D
cell lines were treated with 5-aza-2’-deoxycytidine and
IRF5 expression analyzed by RT-PCR, no change in
transcript levels was detected (data not shown). It has
recently been demonstrated that the IRF5 promoter is
frequently hypermethylated in hepatocellular carcinoma
tissue samples [50]. A similar study in immortalized cell
lines from patients with Li-Fraumeni syndrome that had
decreased IRF5 expression showed no detectable methy-
lation of CpG islands in the IRF5 promoter [51]. More
recently, a single point mutation in the IRF5 gene was
identified in peripheral blood from patients with adult
T-cell leukemia/lymphoma (ATL) and chronic lympho-
cytic leukemia (CLL) that altered the function of wild-
type IRF5 [52]. Together, these data suggest that multi-
ple mechanisms may exist that regulate IRF5 expression
and function in cancer.
Conclusions
Altogether, data presented here support a differential
role for IRF1 and IRF5 in breast tumorigenesis warrant-
ing further investigation regarding prognostic and thera-
peutic implications. While both are important, loss of
each of these factors may play distinct roles in the con-
version of DCIS to IDC and the later metastasis of pri-
mary tumors.
Additional material
Additional file 1: qPCR primers for PCR array confirmation. List of
primers and sequences that were used for qPCR analysis of genes
identified by PCR array.
Additional file 2: IRF5 transcript levels are decreased in
immortalized breast cancer cell lines as compared to immortalized
non-oncogenic mammary epithelial cells. Results from qPCR of IRF5
expression in immortalized mammary cell lines.
Additional file 3: CXCR4 transcript levels are decreased in MDA-MB-
231/pBIRF5 cells. Independent analysis of genes identified from PCR
array by qPCR.
Additional file 4: IRF1 and IRF5 expression are absent in lymph
node mets. Lymph node metastases from IDC patients were stained for
IRF1 and IRF5 expression and analyzed by immunofluorescence.
Additional file 5: IRF5 is highly expressed in immune/inflammatory
cells surrounding normal ducts of IDC patients. IRF1 and IRF5
expression levels were examined by immunofluorescence.
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